Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 399 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Component B Clear all
Suspended Phase 1 Interventional

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

NCT06447987
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Cetuximab, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Not listed Not applicable Interventional

The Management of Diabetes in Everyday Life Program

NCT02957513
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Disease
Interventions
Text Messaging (TM), Health Coaching (HC), Enhanced Usual Care (EC)
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Holly Springs, Mississippi • Bartlett, Tennessee • Covington, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

NCT03077425
View directory record Official record
Conditions
Pediatric Obesity, Early Childhood Caries
Interventions
Enhanced Usual Care (EUC), Intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Months to 2 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
8
States / cities
East Windsor, New Jersey • New Brunswick, New Jersey • Jamaica, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 24, 2026, 8:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

NCT01983761
View directory record Official record
Conditions
Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
Interventions
Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
Drug
Lead sponsor
Targazyme, Inc.
Industry
Eligibility
1 Year to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 24, 2026, 8:50 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04244656
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CTX120
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 24, 2026, 8:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Parents' HPV Stories

NCT06704308
View directory record Official record
Conditions
HPV Vaccination
Interventions
Web Application, Provider Elaborated Prompts
Behavioral
Lead sponsor
Anne E Ray
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Active, not recruiting Not applicable Interventional

Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke

NCT05162781
View directory record Official record
Conditions
Stroke, Cognitive Dysfunction
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living In-lab Training, Cognitive Transfer Packagke, Family Caregiver Coaching, Follow-up Phone Calls, Healthy Lifestyle In-lab Training, Healthy Lifestyle Transfer Package
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Trial of Simulation-based Mastery Learning to Communicate Diagnostic Uncertainty

NCT04021771
View directory record Official record
Conditions
Uncertainty, Communication Research, Emergency Medicine
Interventions
Educational Curriculum Intervention
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

NCT03163901
View directory record Official record
Conditions
Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions
Osteopathic Manipulative Treatment
Other
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mason, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 24, 2026, 8:50 AM EDT
Recruiting Not applicable Interventional

Exciflex Electroceutical Banadage for Chronic Wound Therapy

NCT04887688
View directory record Official record
Conditions
Chronic Wound, Diabetes, Spinal Cord Injury, Ischemic Wound
Interventions
exciflex
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

NCT02260661
View directory record Official record
Conditions
Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
AZD8835, AZD8835 in combination with fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Greenville, South Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 24, 2026, 8:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
22
States / cities
Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional

Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation

NCT06051539
View directory record Official record
Conditions
Chronic Stroke
Interventions
MR-001
Device
Lead sponsor
MedRhythms, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 24, 2026, 8:50 AM EDT
Terminated No phase listed Observational

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

NCT02293408
View directory record Official record
Conditions
MPS IIIB (Sanfilippo B Syndrome)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 1Phase 2 Interventional

Belimumab Impacting Transplant Eligibility

NCT02500251
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
belimumab, Bortezomib, Rituximab, Plasmapheresis
Drug
Lead sponsor
E. Steve Woodle
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 24, 2026, 8:50 AM EDT
Recruiting Phase 1 Interventional

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

NCT05418088
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma
Interventions
Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan, Biopsy, Pheresis, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
Sumithira Vasu
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of HP802-247 in Venous Leg Ulcers

NCT00852995
View directory record Official record
Conditions
Venous Leg Ulcer, Venous Stasis Ulcers
Interventions
HP802-247, Placebo (Vehicle)
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
29
States / cities
Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Attachment Based Family Therapy for Suicidal Adolescents

NCT01537419
View directory record Official record
Conditions
Suicide, Depression, Family Relationships
Interventions
Attachment-Based Family Therapy, Family-Enhanced Non-directive Supportive Therapy
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
12 Years to 18 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional

EMPOWER AUD Pivotal Trial

NCT05948605
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
Interventions
Empower Neuromodulation System
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

NCT02655601
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
Interventions
BMX-001, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 24, 2026, 8:50 AM EDT
Completed Not applicable Interventional

Project IntERact V2

NCT05109325
View directory record Official record
Conditions
Firearm Violence, Firearm Carriage, Injury Prevention
Interventions
IntERact
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 30 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Ann Arbor, Michigan • Flint, Michigan • Saginaw, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 24, 2026, 8:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

B-Fit Intervention to Improve Brain Health

NCT03454074
View directory record Official record
Conditions
Health Behavior, Aging
Interventions
Problem-solving, Education
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 24, 2026, 8:50 AM EDT